Study of sarilumab for early polymyalgia rheumatica
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This trial tests whether the drug sarilumab can help people with newly diagnosed or early relapsing polymyalgia rheumatica (PMR) reduce their need for prednisone. It aims to see if the combination is safer and more effective than prednisone alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years old or older and have been diagnosed with polymyalgia rheumatica (PMR).
- If newly diagnosed, you have been on corticosteroids for 6 weeks or less. If you have had a flare, you must have been on at least 10 mg of prednisone daily for 8 weeks and had a flare in the last 12 weeks while on at least 5 mg daily.
- You are willing and able to take 15 mg of prednisone daily at the start of the study.
- You do not have giant cell arteritis, rheumatoid arthritis, other inflammatory joint diseases, or connective tissue disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is following people who have been recently diagnosed with polymyalgia rheumatica (a condition causing pain and stiffness in the shoulders and hips) and are starting corticosteroid treatment. The goal is to understand the condition's typical course and outcomes over time.
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
This study tests a new injectable medicine (anifrolumab) added to your usual treatments for polymyositis or dermatomyositis. It may help reduce disease activity if you have moderate to severe symptoms and are already on stable therapy.
This trial tests sarilumab, an injected antibody that blocks a key protein involved in inflammation, for people with moderate-to-severe rheumatoid arthritis (RA) who haven't had success with standard treatments. The goal is to see if adding sarilumab can help control joint pain and swelling.
This trial studies sarilumab, a targeted medicine, to help reduce symptoms in children and teens with systemic juvenile idiopathic arthritis (sJIA) who have not responded enough to current treatments. You may be considered because the study looks at how well and safely repeated doses work in pediatric patients.
This trial tests if adding baricitinib (a pill that calms inflammation) to standard steroids works better than steroids alone for people with polymyalgia rheumatica. It aims to improve symptoms and reduce steroid side effects.
Hear when a new Polymyalgia Rheumatica trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.